News · latest 10
Latest Roche news
Showing 10 of 39 dated events. The Signal API returns all of them.
Get them with one API call- Change in Roche’s Board of DirectorsChristophe Weber, Board of Directors
- Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)Roche announced positive interim results from its phase III IMAgINATION study for its investigational drug sefaxersen, which met its primary endpoint of significantly reducing proteinuria in adults with IgA nephropathy (IgAN).
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and...Roche announced positive topline results from a Phase II clinical trial for its investigational drug enicepatide (CT-388), a dual GLP-1/GIP receptor agonist for adults with type 2 diabetes and overweight or obesity.
- European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)Roche's drug Susvimo® has been approved by the European Commission for the treatment of neovascular age-related macular degeneration (nAMD) in Europe.
- CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosisRoche's Ocrevus intravenous infusion has been recommended for approval by the European Medicines Agency's CHMP for treating children and adolescents with relapsing multiple sclerosis, with a final decision from the European Commission expected soon.
- Roche, Dualitas team up to find bispecific drugs for immune diseases$1B · With Dualitas Therapeutics
- Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO studyRoche's phase III CELESTIMO study for its Lunsumio-based regimen met its primary endpoint, demonstrating a significant improvement in progression-free survival for patients with relapsed or refractory follicular lymphoma.
- U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentsWith U.S. Food and Drug Administration
- Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood TestWith Treeline Biosciences
Showing 10 of 39 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Roche with the Signal API
One POST /v1/companies/enrich call with roche.com returns Roche news signals (news), each with its source. Or ask Claude through MCP.
Start Free1,000 free creditsUse it in Claude via MCP
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"roche.com","signal_types":["news"],"limit":20}'Same industry
News at related companies
Questions about Roche news
What is the latest news on Roche?
The newest event on this page is dated Sep 23, 2026. globenewswire.com reported: Change in Roche’s Board of Directors. This page lists 39 dated events for Roche, each with a source link.
What is going on with Roche?
The 10 latest events on this page cover executive hire (1), in development (5), launch (1), partnership (2) and new location (1). The newest: Sep 23, 2026: Change in Roche’s Board of Directors (globenewswire.com).
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .